Mesoblast Presents Respiratory Function Results of COVID-19 ARDS Trial at Pulmonary Disease Conference
15. Juli 2021 20:15 ET
|
Mesoblast Limited
NEW YORK, July 15, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today presented clinical outcomes from...
Mesoblast Provides Update on Program for Chronic Low Back Pain Due to Degenerative Disc Disease
30. Juni 2021 19:46 ET
|
Mesoblast Limited
NEW YORK, June 30, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on the...
Operational Highlights and Financial Results for the Period Ended March 31, 2021
02. Juni 2021 20:01 ET
|
Mesoblast Limited
NEW YORK, June 02, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today reported operational highlights...
Mesoblast Corporate Update and Financial Results Webcast
02. Juni 2021 18:01 ET
|
Mesoblast Limited
NEW YORK, June 02, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast today to discuss...
Improved Outcomes in Inflammatory Lung Disease With Remestemcel-L Published in Respiratory Research Journal
25. Mai 2021 07:00 ET
|
Mesoblast Limited
NEW YORK, May 25, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that the peer-reviewed...
Appendix 4C Quarterly Activity Report
29. April 2021 20:47 ET
|
Mesoblast Limited
NEW YORK, April 29, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on its...
Remestemcel-L Reduces Mortality in Patients Less Than 65 Years Old With Moderate/Severe COVID-19 ARDS: Topline 60-Day Results From Randomized Controlled Trial
29. April 2021 19:32 ET
|
Mesoblast Limited
Remestemcel-L reduced mortality through 60 days in the pre-specified population under 65 years oldIn these patients the benefit was further increased when remestemcel-L was used with dexamethasone as...
Mesoblast Corporate Update
29. April 2021 19:08 ET
|
Mesoblast Limited
NEW YORK, April 29, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast today to provide...
Mesoblast Operational Highlights and Upcoming Milestones
30. März 2021 19:54 ET
|
Mesoblast Limited
NEW YORK, March 30, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an overview of the...
Philip J. Facchina, Chief Strategy Officer and Principal of SurgCenter Development, Joins Mesoblast Board
29. März 2021 08:00 ET
|
Mesoblast Limited
NEW YORK, March 29, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that Philip J....